Close Menu

Many pharmaceutical companies have been cutting their R&D budgets, and now, many biotechs are following suit, says Pharmalot's Ed Silverman. Even as biotech revenues are rising, companies are keeping hold of their cash and spending less on innovative research. "Overall, biotechs spent $54 million on R&D in 2010, which is down 7 percent from the previous year. This followed a 9 percent decline in spending in 2009," Silverman says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.